Stifel Financial Corp Grows Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Stifel Financial Corp grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 103.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 440,666 shares of the company’s stock after purchasing an additional 224,594 shares during the period. Stifel Financial Corp’s holdings in Takeda Pharmaceutical were worth $6,266,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of TAK. Cetera Advisors LLC purchased a new stake in Takeda Pharmaceutical in the first quarter worth $240,000. Envestnet Portfolio Solutions Inc. increased its stake in Takeda Pharmaceutical by 15.9% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 29,870 shares of the company’s stock worth $387,000 after purchasing an additional 4,107 shares during the period. Blue Trust Inc. increased its stake in Takeda Pharmaceutical by 74.0% in the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after purchasing an additional 2,330 shares during the period. Raymond James & Associates grew its position in shares of Takeda Pharmaceutical by 5.3% during the 2nd quarter. Raymond James & Associates now owns 255,762 shares of the company’s stock worth $3,310,000 after buying an additional 12,862 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Takeda Pharmaceutical by 40.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 10,907 shares of the company’s stock worth $141,000 after buying an additional 3,143 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK opened at $13.42 on Friday. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The business’s fifty day simple moving average is $13.81 and its 200-day simple moving average is $13.87. The company has a market capitalization of $42.70 billion, a price-to-earnings ratio of 23.14, a PEG ratio of 0.26 and a beta of 0.51.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.